Bragar Eagel & Squire Urges Aardvark Therapeutics Investors to Contact Firm
Law firm Bragar Eagel & Squire, P.C. has filed a class action lawsuit against Aardvark Therapeutics. Investors have until October 13th to apply to be appointed as lead plaintiff.
A class action lawsuit has been filed against Aardvark Therapeutics, Inc. (NASDAQ: AARD) in the U.S. District Court for the Southern District of California. Bragar Eagel & Squire, P.C. is representing individuals and entities who purchased Aardvark common stock pursuant to its February 13, 2025 initial public offering (IPO) or securities between February 13, 2025, and May 14, 2026.
The lawsuit alleges that defendants made materially false and misleading statements and failed to disclose adverse facts about Aardvark's business. Specifically, it claims that ARD-101 was less safe than represented and that its clinical, regulatory, and commercial prospects were overstated. Investors allegedly suffered damages when the true details emerged.
Investors who purchased Aardvark securities during the specified period and suffered losses are encouraged to contact Bragar Eagel & Squire to discuss their legal options. The deadline to apply for appointment as lead plaintiff is October 13, 2026.
Bragar Eagel & Squire, P.C. is a nationally recognized law firm specializing in shareholder rights litigation, with offices in New York, South Carolina, and California.